350 related articles for article (PubMed ID: 29098608)
1. Novel Therapies for Myelofibrosis.
Pettit K; Odenike O
Curr Hematol Malig Rep; 2017 Dec; 12(6):611-624. PubMed ID: 29098608
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
3. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for myelofibrosis.
Atallah E; Verstovsek S
Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
[TBL] [Abstract][Full Text] [Related]
5. State-of-the-Art Review on Myelofibrosis Therapies.
Wang F; Qiu T; Wang H; Yang Q
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
[TBL] [Abstract][Full Text] [Related]
6. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract][Full Text] [Related]
7. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
8. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
9. Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
Mascarenhas J
Leuk Lymphoma; 2015; 56(9):2493-7. PubMed ID: 25586607
[TBL] [Abstract][Full Text] [Related]
10. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
11. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
Stein BL; Swords R; Hochhaus A; Giles F
Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
[TBL] [Abstract][Full Text] [Related]
12. Management of myelofibrosis: JAK inhibition and beyond.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
[TBL] [Abstract][Full Text] [Related]
13. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
15. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
Diaz AE; Mesa RA
Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
[TBL] [Abstract][Full Text] [Related]
16. Clarifying the use of ruxolitinib in patients with myelofibrosis.
Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
[TBL] [Abstract][Full Text] [Related]
17. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutics and targets in myelofibrosis.
Waksal JA; Harrison CN; Mascarenhas JO
Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
20. Management of myelofibrosis after ruxolitinib failure.
Bose P; Verstovsek S
Leuk Lymphoma; 2020 Aug; 61(8):1797-1809. PubMed ID: 32297800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]